

<https://helda.helsinki.fi>

Metabolomic Fingerprints in Large Population Cohorts : Impact of Preanalytical Heterogeneity

Ghini, Veronica

2021-08

Ghini , V , Abuja , P M , Polasek , O , Kozera , L , Laiho , P , Anton , G , Zins , M , Klovins , J , Metspalu , A , Wichmann , H-E , Gieger , C , Luchinat , C , Zatloukal , K & Turano , P 2021 , ' Metabolomic Fingerprints in Large Population Cohorts : Impact of Preanalytical Heterogeneity ' , Clinical Chemistry (Washington, DC) , vol. 67 , no. 8 , pp. 1153-1155 . <https://doi.org/10.1093/clinchem/hvab092>

<http://hdl.handle.net/10138/335124>

<https://doi.org/10.1093/clinchem/hvab092>

cc_by_nc_nd

publishedVersion

Downloaded from Helda, University of Helsinki institutional repository.

This is an electronic reprint of the original article.

This reprint may differ from the original in pagination and typographic detail.

Please cite the original version.

Metabolomic Fingerprints in Large Population Cohorts: Impact of Preanalytical Heterogeneity

To the Editor:

Metabolomics studies have provided new insights into molecular disease mechanisms and individual response to treatment. Large scale metabolomics studies can greatly contribute to building a solid data and knowledge basis for future disease prevention strategies as well as better diagnostic and therapeutic approaches (1). A prerequisite, however, is that data from a sufficient number of bio-samples are available. This goal can only be achieved by gathering many samples from different cohorts and requiring that the quality of these samples is appropriate to generate reliable and reproducible results.

The impact of the preanalytical procedures on the stability of the human metabolome has been previously described. In particular, systematic simulation of different preanalytical procedures performed on urine and blood serum and plasma have highlighted how the concentration of some key metabolites is altered via 2 main mechanisms: enzymatic activity, mainly, but not exclusively, attributable to the presence of cells; and redox reactions occurring among metabolites and between metabolites and dioxygen (2, 3). The results have led to the development of

international specifications such as the 2016 European Committee for Standardization (CEN)/TS 16 945 Specifications for molecular in vitro diagnostic examinations—Specifications for preexamination processes for metabolomics in urine, venous blood serum, and plasma.


We performed a comprehensive nuclear magnetic resonance (NMR)-based metabolomics study of human blood serum and plasma (EDTA-plasma) from, respectively, 5 and 8 leading European population cohorts from the BBMRI-LPC consortium. We addressed the extent to which samples of different cohorts were suitable to be used together for metabolomics studies and whether data integration of studies performed on such samples was feasible and reliable. The analysis was performed via ^1H NMR, a highly reproducible tool for untargeted fingerprinting and profiling (4), where all metabolites above the 1 μM detection limit were measured simultaneously. Each participating biobank provided serum and plasma samples from 30 healthy volunteers with equal share of males and females.

Multivariate statistics revealed a clear discrimination of the samples based on the biobank of origin. The accuracy for classification (96% for plasma and 98% for serum, Fig. 1) was assessed by means of a Monte Carlo cross-validation scheme; each dataset was randomly divided into a training set (90% of the data) and a test set (10% of the data). The training set was used to build the model, whereas the test set was used to validate its discriminant and predictive power; this operation was repeated 500 times. The differences were mainly attributable to a small but relevant set of metabolites that showed different mean concentration values in samples from different biobanks. From an ex post analysis of the standard operating procedures adopted by

each biobank, we could interpret the observed trends in terms of differences in preanalytical procedures. A major effect was attributable to the delayed separation of plasma and serum from the blood cellular components; erythrocytes, when removed from the circulation, exhibit severe disturbance of the glycolytic flow (5), which manifests itself mainly in glucose consumption and lactate accumulation. In fact, unusual concentrations of these 2 metabolites, which are key biomarkers of a series of metabolic dysfunctions, were observed for the biobanks allowing for 72 h delayed sample preparation (i.e., centrifugation). Another critical step concerned the delay between serum/plasma separation and sample freezing. This phase is not adequately regulated by the standard operating procedures of the various biobanks, which translates, for example, into variable concentrations of citrate within samples from the same biobanks as well as from the different biobanks.

The situation of Fig. 1 is often encountered in metabolomics studies based on multicenter cohorts whenever samples are not collected under strictly controlled conditions, and can be aggravated by the use of different additives (such as gel separators) that might interfere with components of the sample metabolome. The inaccurate quantification of small molecule biomarkers might severely affect the outcome of metabolomics studies, introducing artificial noise, and thus weakening the profiling performance of the analytical method. In summary, 2 main conclusions can be derived from the present contribution. First, samples from existing cohorts should be used with care and possibly after reviewing the operating procedures adopted for sample collection, processing, and storage. Second, the biobanks interested in creating novel collections to be used for metabolomics must

©American Association for Clinical Chemistry 2020.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (<http://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com



adopt procedures that comply with the existing CEN/ISO standards.

Nonstandard Abbreviations: CEN, European Committee for Standardization; NMR, Nuclear Magnetic Resonance; BBMRI-LPC, Biobanking and Biomolecular Research Infrastructure-Large Prospective Cohorts; ISO, International Organization for Standardization

Author Contributions: All authors confirmed they have contributed to the intellectual content of this paper and have met the following 4 requirements: (a) significant contributions to the conception and design, acquisition of data, or analysis and interpretation of data; (b) drafting or revising the article for intellectual content; (c) final approval of the published article; and (d) agreement to be accountable for all aspects of the article thus ensuring that questions related to the accuracy or integrity of any part of the article are appropriately investigated and resolved.

P. Turano, K. Zatloukal, C. Luchinat, and P.M. Abuja conceived this study; V. Ghini performed the metabolomic analyses; P. Turano and V. Ghini interpreted the NMR results. O. Polasek, L. Kozera, P. Laiho, G. Anton, M. Zins, J. Klovins, and A. Metspalu provided biobank samples and anonymized

patient data. P. Turano, V. Ghini, and C. Luchinat drafted the initial manuscript. K. Zatloukal, P.M. Abuja, C. Gieger, and H-E. Wichmann contributed to the manuscript writing, which all authors subsequently revised. All authors approved the final version of the work.

Authors' Disclosures or Potential Conflicts of Interest: Upon manuscript submission, all authors completed the author disclosure form. Disclosures and/or potential conflicts of interest:

Employment or Leadership: P.M. Abuja, Medical University of Graz; G. Anton, Helmholtz Center Munich.

Consultant or Advisory Role: None declared.

Stock Ownership: None declared.

Honoraria: None declared.

Research Funding: This research has received funding from the EU Horizon 2020 research and innovation program under the project SPIDIA4P (GA no. 733,112) and former FP7 projects BBMRI-LPC (GA no. 313010) and SPIDIA (GA no. 222916). A. Metspalu was supported by Gentransmed (Project No. 2014-2020.4.01.15-0012). V. Ghini was supported by an AIRC/FIRC fellowship for Italy.

Expert Testimony: None declared.

Patents: None declared.

References

1. Suhre K, Shin S-Y, Petersen A-K, Mohny RP, Meredith D, Wägele B, et al Human metabolic individuality in biomedical and pharmaceutical research. *Nature* 2011; 477:54-60.
2. Kamlage B, Maldonado SG, Bethan B, Peter E, Schmitz O, Liebenberg V, et al Quality markers addressing pre-analytical variations of blood and plasma processing identified by broad and targeted metabolite profiling. *Clin Chem* 2014;60:399-412.
3. Ghini V, Quaglio D, Luchinat C, Turano P. NMR for sample quality assessment in metabolomics. *New Biotechnol* 2019;52:25-34.
4. Takis PG, Ghini V, Tenori L, Turano P, Luchinat C. Uniqueness of the NMR approach to metabolomics. *Trends Anal Chem* 2019;120:115300.
5. Tilton WM, Seaman C, Carriero D, Piomelli S. Regulation of glycolysis in the erythrocyte: role of the lactate/pyruvate and NAD/NADH ratios. *J Lab Clin Med* 1991;118:146-52.

Veronica Ghini,^a Peter M. Abuja,^b Ozren Polasek,^{c,d} Lukasz Kozera,^e Päivi Laiho,^f Gabriele Anton,^g Marie Zins,^h Janis Klovins,ⁱ Andres Metspalu,^j H-Erich Wichmann,^k Christian Gieger,^k Claudio Luchinat,^{a,i,m}

Kurt Zatloukal^{b,*} and
Paola Turano^{a,l,m,*}

^aConsorzio Interuniversitario
Risonanze Magnetiche di Metallo
Proteine (CIRMP), Sesto Fiorentino
(FI), Italy

^bDiagnostic and Research Center for
Molecular Biomedicine, Institute of
Pathology, Medical University of Graz,
Graz, Austria

^cDepartment for Large Population
Studies, University of Split, Split,
Croatia

^dGen-Info Ltd, Zagreb, Croatia

^eBBMRI-ERIC, Graz, Austria

^fInstitute for Molecular Medicine
Finland, & National Institute for Health
and Welfare, THL, University of
Helsinki, Helsinki, Finland

^gMolecular Epidemiology, Helmholtz-
Zentrum München, Neuherberg,
Germany

^hPopulation-based Epidemiological
Cohorts Unit-UMS 11, Inserm, Villejuif,
France

ⁱLatvian Biomedical Research and
Study Centre, Riga, Latvia

^jEstonian Genome Centre, Institute of
Genomics, University of Tartu, Tartu,
Estonia

^kInstitute of Epidemiology, Helmholtz
Center Munich, Neuherberg,
Germany

^lCenter of Magnetic Resonance
(CERM), University of Florence, Sesto
Fiorentino (FI), Italy

^mDepartment of Chemistry,
University of Florence, Sesto
Fiorentino (FI), Italy.

*Address correspondence to: K.Z. at
Institute of Pathology, MUG, Neue
Stiftingtalstrasse 6, A-8010 Graz,
Austria. Fax +43 (0)316 385 71731;
e-mail: kurt.zatloukal@medunigraz.at.
P.T. at CERM, University of Florence,
via Luigi Sacconi 6, 50019, Sesto
Fiorentino (FI) Italy. Fax +39
0554574266; e-mail
turano@cerm.unifi.it.

A Large Number of Fresh Samples and a Wide Range of Total Prostate-Specific Antigen (tPSA) Concentrations Is Important to Detect Differences in PSA Methods

To the Editor:

Harmonization among total prostate-specific antigen (tPSA) assays will help mitigate both patient and clinician confusion regarding disparate results obtained from various manufacturers. Despite standards being established in 1999, the 2008 recommendation from the National Academy of Clinical Biochemistry laboratory practice guidelines to include the manufacturer of the tPSA on the report is still prudent (1). The recent paper by Ferraro and colleagues further emphasizes the need that patients be monitored by the same method (or measuring system, MS) but also states “that the remaining clinically relevant systematic biases among MSs could be successfully removed by a mathematical recalibration process by using a suitable reference material” (2). This is an intriguing statement that depends at least in part in a mathematical relationship that is consistent over a large number of samples, over a wider and higher analytical range, and with different MSs.

In their publication, Ferraro and colleagues use a sufficient number of samples ($n = 135$ serum samples for tPSA) for the method comparisons as suggested by Linnet (3). However, the results reported in the publication only ranged from approximately 1 µg/L to 50 µg/L and tPSA was measured by only 4

MSs (Abbott Alinity, Beckman Access, Roche Cobas, and Siemens Atellica) (2). This range does not capture those patients with very low concentrations (i.e., Abbott tPSA <0.97 µg/L) or with very high concentrations (Abbott tPSA >48.8 µg/L) who are routinely observed in clinical practice (4). Moreover, the 4 MSs do not capture all relevant MSs. According to the combined Institute for Quality Management in Healthcare (Canada) and the Royal College of Pathologists of Australasia Quality Assurance Programs, approximately 12% of more than 200 sites use the Ortho Clinical Diagnostics MS for tPSA measurement (see October 2, 2020 issued report). As our hospital site recently transitioned from the Abbott ARCHITECT tPSA assay to the Ortho VITROS XT 7600 tPSA assay, our objective was to assess the percentage difference between Ortho tPSA from Abbott tPSA across various analytical ranges in fresh serum samples tested by both methods over 15 weeks (dual reporting to enable rebaselining tPSA) (4, 5).

During the period of dual reporting (May 2020 to August 2020 to allow clinicians to rebaseline patients), there were 1101 samples reported by both tPSA methods, with 18% yielding at least 1 result below the limit of quantification (LoQ) for either assay. For the 538 samples falling within the 0.97 µg/L to 48.8 µg/L range used in the Ferraro study, the median (25th to 75th percentiles) percentage difference [(Ortho tPSA – Abbott tPSA)/Abbott tPSA × 100%] was 14.6% (8.6 to 21.0). A similar difference of 13.3% (8.0 to 20.0) was observed in the LoQ to 0.96 µg/L samples ($n = 265$) ($P = 0.35$, Kruskal–Wallis all pairwise comparisons with Conover-Iman, StatsDirect Statistical Software v.3.2.7). However, for the 103 samples above 48.8 µg/L, the percentage